Institut National De La Sante Et De La Recherche Medicale

UniversitÉde Strasbourg

Etablissement Francais Du Sang

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Etablissement Francais Du Sang (efs)

Etablissment Françis Du Sang

Christian Gachet

Kenneth Alan Jacobson

Yoonkyung Kim

Francine Rendu

Jean-Pierre Cazenave

Athena Klutz

Beatrice Hechler

François Lanza

Pierre Mangin

Thibault Donnet

Blandine Maitre

Catherine Angenieux

Catherine Strassel

Nathalie Brouard

Henri De La Salle

The present invention relates to a method for analyzing the platelets present in a blood sample, said method comprises the steps of (a) adding to said sample a ligand which binds to the MCH I coupled to a fluorochrome, (b) measuring the mean fluorescence intensity of the platelets (MFI) with a flow cytometer and c) measuring the mean 'Forward Scatter' parameter (FSC) with said flow cytometer and determining the MFI/FSC ratio. The invention also relates to an in vitro method for diagnosing a peripheral or central thrombocytopenia in a subject.

Method for analyzing the platelets of a blood sample

The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.

Methods and pharmaceutical compositions for the prophylactic treatment of metastases

The invention relates to a method of producing CD34+CD4megakaryocyte (MK) progenitor cells, and substantially pure cell population of megakaryocyte precursor cells obtained by said method. The invention also relates to a method of producing proplatelet-bearing MKs and/or platelets using the CD34+CD4cells.

CD34CD41megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets

The present invention relates to a new method for the preservation of blood platelets. In particular, the present invention provides a method which includes submitting the platelets to zeodration carried out at temperatures between 18&#xb0; C. and 24&#xb0; C. The dried platelets thus obtained can be preserved at room temperature for long period of time. The invention also provides kits and compositions for using the preserved platelets.

Zeodration method for the preservation of blood platelets

Disclosed are conjugates comprising a dendrimer and a ligand, which is a functionalized congener of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily, for example, wherein the functionalized congener is an Aadenosine receptor agonist having a purine nucleoside moiety and a functional group at the Nposition of the purine nucleoside moiety, wherein the functional group has the formula (I): NH&#x2014;Ar&#x2014;CH&#x2014;C(&#x2550;O)NH&#x2014;R(I), wherein Arand Ras defined herein. Also disclosed are pharmaceutical compositions, methods of treating various diseases, and a diagnostic method employing such conjugates.

Dendrimer conjugates of agonists and antagonists of the GPCR superfamily

Growing community of inventors

Lalaye, France

Christian Gachet